On 8th February 2012, the US-FDA issued a new warning on several popular proton pump inhibitors (PPI). The agency warned that the use of certain heartburn and acid reflux drugs might increase the risk of Clostridium difficile-associated diarrhea (CDAD). The agency also suggested considering a diagnosis of CDAD for patients taking PPIs who developed diarrhea that does not improve.
The FDA issued this safety announcement just after the review of reports from the AERS (Adverse Event Reporting System) and the medical literature suggested such a link with PPIs.
According to FDA's website, the warning applies to the following both prescription and over-the-counter PPIs:
2. Omeprazole and sodium bicarbonate
3. Esomeprazole magnesium
4. Pantoprazole sodium
5. Rabeprazole sodium
Furthermore, you need to know that PPIs have already linked with several other adverse events, including arrhythmias, seizures, clopidogrel resistance, osteoporotic fractures, cardiac birth defects, and decrease in magnesium levels resulting in an increased risk of leg spasms.
The FDA safety announcement also reported that the agency has already started working with these drug manufacturers for modifying the labels to include the warning regarding increased risk of Clostridium difficile-associated diarrhea.
Additionally, you need to know that Clostridium difficile (C. difficile) is a bacterium, which causes a serious diarrhea that rarely improve. Its symptoms Include:
a) Water like stool
b) Serious intestinal discomforts
c) Pain in abdomen and fever
Get Some Cool Stuffin your inbox
Subscribe to our blog and get free health and medical updates to your email inbox.
Your information is safe with us. We value your privacy and take data protection seriously.
FDA Issued Warning on Several Proton Pump Inhibitors
About the Author
Imtiaz is the founder and editor of Medical-Reference. He is a certified health care professional (pharmacist) and a freelance medical writer. He holds a Bachelor's in Pharmacy from Bangladesh. Learn more about him here and connect with him on Twitter, Facebook, and Google+.